0001181431-13-033361.txt : 20130606 0001181431-13-033361.hdr.sgml : 20130606 20130606215850 ACCESSION NUMBER: 0001181431-13-033361 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130604 FILED AS OF DATE: 20130606 DATE AS OF CHANGE: 20130606 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8424 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaye Edward M. MD CENTRAL INDEX KEY: 0001522780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 13898773 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY CITY: BOTHELL STATE: WA ZIP: 98011 4 1 rrd382733.xml FORM 4 X0306 4 2013-06-04 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001522780 Kaye Edward M. MD 215 FIRST STREET, SUITE 7 CAMBRIDGE MA 02412 0 1 0 0 SVP & Chief Medical Officer Incentive Stock Option (right to buy) 34.9200 2013-06-04 4 A 0 2863 0.00 A 2023-06-04 Common Stock 2863 2863 D Non-Qualified Stock Option (right to buy) 34.9200 2013-06-04 4 A 0 42137 0.00 A 2023-06-04 Common Stock 42137 42137 D Non-Qualified Stock Option (right to buy) 34.9200 2013-06-04 4 A 0 45000 0.00 A 2023-06-04 Common Stock 45000 45000 D This option is exercisable at the rate of 25% of the shares on the first anniversary of the date of grant and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of grant. In the event of the achievement of certain performance milestones prior to January 1, 2017, the shares subject to the option will vest and become exercisable with respect to 1/4th of the total number of shares subject to the option on June 4, 2014 and 1/48th of the original number of shares subject to the option monthly thereafter, subject to continued service with the Issuer. On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders. By: David Tyronne Howton For: Edward M. Kaye MD 2013-06-06